Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 2/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | Q9HBH1 | 1/20 | 0.39 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042978 | 0.86 | F2 (0.52) | F2LMNAALDH1A1SMN1; SMN2EP300 | |
| SCHEMBL3045320 | 0.86 | F2 (0.52) | F2LMNAALDH1A1SMN1; SMN2EP300 | |
| SCHEMBL18887550 | 0.86 | F2 (0.52) | F2LMNAALDH1A1SMN1; SMN2EP300 | |
| SCHEMBL13379461 | 0.82 | NPC1 (0.58) | LMNAALDH1A1SMN1; SMN2EP300CREBBP | |
| SCHEMBL3043835 | 0.80 | KCNH2 (0.45) | F2CNR2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL13379445 | 0.80 | LMNA (0.46) | LMNAALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL3040998 | 0.78 | CYP2C19 (0.56) | LMNAALDH1A1SMN1; SMN2GAAEP300 | |
| SCHEMBL18887499 | 0.78 | CYP2C19 (0.56) | LMNAALDH1A1SMN1; SMN2GAAEP300 | |
| SCHEMBL14723789 | 0.78 | KCNH2 (0.55) | F2LMNAALDH1A1EP300CREBBP | |
| SCHEMBL3049175 | 0.76 | EP300 (0.61) | LMNAALDH1A1SMN1; SMN2EP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328865-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-8383094-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-20100080772-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080772-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | F2 1997/4885CNR2 3204/4885LMNA 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.